Sylvania Platinum Ltd 42.8% potential upside indicated by Liberum Capital

Sylvania Platinum Ltd with ticker (LON:SLP) now has a potential upside of 42.8% according to Liberum Capital.



Liberum Capital set a target price of 170 GBX for the company, which when compared to the Sylvania Platinum Ltd share price of 97 GBX at opening today (08/11/2021) indicates a potential upside of 42.8%. Trading has ranged between 64 (52 week low) and 150 (52 week high) with an average of 1,131,502 shares exchanging hands daily. The market capitalisation at the time of writing is £265,420,629.

Simulations Plus, Inc. is a developer of drug discovery and development software for mechanistic modeling and simulation, for machine-learning-based prediction of properties of molecules from their structure, and is exploring the application of its machine-learning technologies in other industries, including aerospace/military and general healthcare. The Company offers its products and services through two business segments, which include Simulations Plus, Inc. and Cognigen Corporation. Cognigen Corporation is the subsidiary of the Company. Its pharmaceutical/chemistry software is used by various companies, such as pharmaceutical, biotechnology, agrochemical, and food industry companies and to regulatory agencies for use in the conduct of industry-based research. Its clinical-pharmacology-based consulting services include pharmacokinetic and pharmacodynamics modeling, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions.